HSPH1 and melanoma: Since human gp100-specific CD8+ T cells were greater in the clinically responding patients with advanced melanoma in the hsp110-gp100 vaccine trial (11), our data suggest that the chitosan-based delivery of RNA-interfering therapeutic may be a promising approach to be exploited for promoting antitumor efficacy of chaperone vaccines in future clinical trials.